A patient with Lynch syndrome experienced complete pancreatic cancer regression and remained cancer-free for 10 years after enrolling in a checkpoint inhibitor trial.

“had developed uh panc creatic cancer and when he went to see the surgeon um they said yeah we there's nothing we can do like it's too advanced so that's you know to put that in perspective that is a death sentence and that's not a that that's a that's a six-month survival and at around that time there was a study that had come out in the New England Journal of Medicine that had talked about how patients with Lynch syndrome had lots of mutations and so we you know talked with his doctors about the possibility of enrolling him in one of the kit truda trials there was one going on I think at Stanford and you know the thinking being well you know you would want to Target a checkpoint inhibitor against somebody who has a lot of mutations and even though typically we don't see that in pancreatic cancer his is a unique variant of it because it's based on this and so sure enough he was tested for these mismatch repair genes he had them enrolled in the trial and amazingly had not only a complete regression of his cancer and he's still alive and cancer-free today 10 years later”